Expert warns that newer obesity GLP-1 drugs could spark access battles in low-income nations
Lower‑cost generic versions of semaglutide, sold as Wegovy for obesity, have begun appearing in several markets and are expected to reach more countries soon. At the same time, pharmaceutical companies are racing to create next‑generation GLP‑1 medicines that promise greater efficacy, fewer side effects, and easier administration.
Ken Shadlen, a professor at the London School of Economics who studies pharmaceutical policy, cautions that these newer obesity treatments may become the next major arena for disputes over drug access in low‑income nations. He argues that without proactive measures, the gap between high‑priced innovative drugs and the ability of poorer countries to obtain them could widen.
Shadlen suggests drugmakers should develop licensing strategies now to ensure broader availability if the newer agents reach the market. Preparing such plans early could help mitigate future conflicts over pricing and distribution, and support global efforts to address obesity.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity”
read at STAT ↗
comments(0)
5-min edit window · permanent after that